A组链球菌疫苗研究进展
|
摘要
A组链球菌是(GAS)一种常见的革兰阳性病原菌,人是其唯一自然宿主。GAS感染人体后可导致一系列感染性疾病,还可引起一些自身免疫性疾病,严重危害人体健康,同时也给社会带来巨大的经济负担。目前,GAS对青霉素仍然敏感,但对其他抗生素的耐药率不断增加。预防GAS感染最好的方法是研制安全、有效的疫苗。GAS疫苗的研究已经持续了近百年,但迄今还没有商品化的疫苗研制出来。现在有多种疫苗正处于不同的研发阶段之中,该文就GAS疫苗的研究进展进行概述。
Group A streptococcus(GAS) is a common gram-positive pathogenic bacterium.Human is the only natural host of GAS.GAS infection can lead to a wide spectrum of infectious diseases and several autoimmune diseases,which seriously damages human health and brings significant economic burden to the society.Currently,GAS is still sensitive to penicillin,but it yields increasing resistance to other antibiotics.The best strategy to prevent GAS infection is to develop a safe and effective vaccine.Even though investigated for almost 100 years,no commercial vaccine for GAS has been developed worldwide.Multiple types of vaccine candidates are being investigated in different stages.In this paper,recent research progress on GAS vaccine was reviewed.
Group A streptococcus(GAS) is a common gram-positive pathogenic bacterium.Human is the only natural host of GAS.GAS infection can lead to a wide spectrum of infectious diseases and several autoimmune diseases,which seriously damages human health and brings significant economic burden to the society.Currently,GAS is still sensitive to penicillin,but it yields increasing resistance to other antibiotics.The best strategy to prevent GAS infection is to develop a safe and effective vaccine.Even though investigated for almost 100 years,no commercial vaccine for GAS has been developed worldwide.Multiple types of vaccine candidates are being investigated in different stages.In this paper,recent research progress on GAS vaccine was reviewed.
引文
[1]Steer AC,Law I,Matatolu L,Beall BW,Carapetis JR.Global emm type distribution of group A streptococci:systematic review and implications for vaccine development.Lancet Infect Dis,2009,9(10):611-616.
[2]Carapetis JR,Steer AC,Mulholland EK,Weber M.The global burden of group A streptococcal diseases.Lancet Infect Dis,2005,5(11):685-694.
[3]Bowen AC,MahéA,Hay RJ,Andrews RM,Steer AC,Tong SY,Carapetis JR.The global epidemiology of impetigo:a systematic review of the population prevalence of impetigo and pyoderma.PLo S One,2015,10(8):e0136789.
[4]Pfoh E,Wessels MR,Goldmann D,Lee GM.Burden and economic cost of group A streptococcal pharyngitis.Pediatrics,2008,121(2):229-234.
[5]Martin WJ,Steer AC,Smeesters PR,Keeble J,Inouye M,Carapetis J,Wicks IP.Post-infectious group A streptococcal autoimmune syndromes and the heart.Autoimmun Rev,2015,14(8):710-725.
[6]Mcmillan DJ,Drèze PA,Vu T,Bessen DE,Guglielmini J,Steer AC,Carapetis JR,Van Melderen L,Sriprakash KS,Smeesters PR.Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.Clin Microbiol Infect,2013,19(5):E222-E229.
[7]喻刚,董太明,全家妩.A群链球菌疫苗的研究进展.中国生物制品学杂志,2009,22(8):830-833.
[8]Dale JB,Penfound TA,Tamboura B,Sow SO,Nataro JP,Tapia M,Kotloff KL.Potential coverage of a multivalent M proteinbased group A streptococcal vaccine.Vaccine,2013,31(12):1576-1581.
[9]Sanderson-Smith M,De Oliveira DM,Guglielmini J,Mcmillan DJ,Vu T,Holien J K,Henningham A,Steer AC,Bessen DE,Dale JB,Curtis N,Beall BW,Walker MJ,Parker MW,Carapetis JR,Van Melderen L,Sriprakash KS,Smeesters PR;M Protein Study Group.A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.J Infect Dis,2014,210(8):1325-1338.
[10]Steer AC,Carapetis JR,Dale JB,Fraser JD,Good MF,Guilherme L,Moreland NJ,Mulholland EK,Schodel F,Smeesters PR.Status of research and development of vaccines for Streptococcus pyogenes.Vaccine,2016,34(26):2953-2958.
[11]Steer AC,Law I,Matatolu L,Beall BW,Carapetis JR.Global emm type distribution of group A streptococci:systematic review and implications for vaccine development.Lancet Infect Dis,2009,9(10):611-616.
[12]Dale JB,Niedermeyer SE,Agbaosi T,Hysmith ND,Penfound TA,Hohn CM,Pullen M,Bright MI,Murrell DS,Shenep LE,Courtney HS.Protective immunogenicity of group A streptococcal M-related proteins.Clin Vaccine Immunol,2015,22(3):344-350.
[13]Courtney HS,Niedermeyer SE,Penfound TA,Hohn CM,Greeley A,Dale JB.Trivalent M-related protein as a component of next generation group A streptococcal vaccines.Clin Exp Vaccine Res,2017,6(1):45-49.
[14]Batzloff M,Yan H,Davies M,Hartas J,Good M.Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection.Indian J Med Res,2004,119 Suppl:104-107.
[15]Pandey M,Wykes MN,Hartas J,Good MF,Batzloff MR.Longterm antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.J Immunol,2013,190(6):2692-2701.
[16]Batzloff MR,Fane A,Gorton D,Pandey M,Rivera-Hernandez T,Calcutt A,Yeung G,Hartas J,Johnson L,Rush CM,McCarthy J,Ketheesan N,Good MF.Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.Hum Vaccin Immunother,2016,12(12):3089-3096.
[17]Guilherme L,Postol E,Ferreira FM,De Marchi LM,Kalil J.Strept In Cor:a model of anti-Streptococcus pyogenes vaccine reviewed.Auto Immun Highlights,2013,4(3):81-85.
[18]Guilherme L,Ferreira FM,K9hler KF,Postol E,Kalil J.A vaccine against Streptococcus pyogenes:the potential to prevent rheumatic fever and rheumatic heart disease.Am J Cardiovasc Drugs,2013,13(1):1-4.
[19]Marshall HS,Richmond P,Nissen M,Lambert S,Booy R,Reynolds G,Sebastian S,Pride M,Jansen KU,Anderson AS,Scully IL.Group A streptococcal carriage and seroepidemiology in children up to 10 years of age in Australia.Pediatr Infect Dis J,2015,34(8):831-838.
[20]Cleary PP,Matsuka YV,Huynh T,Lam H,Olmsted SB.Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.Vaccine,2004,22(31-32):4332-4341.
[21]Steer AC,Batzloff MR,Mulholland K,Carapetis JR.Group A streptococcal vaccines:facts versus fantasy.Curr Opin Infect Dis,2009,22(6):544-552.
[22]Courtney HS,Pownall HJ.The structure and function of serum opacity factor:a unique streptococcal virulence determinant that targets high-density lipoproteins.J Biomed Biotechnol,2010,2010:956071.
[23]Ma CQ,Li CH,Wang XR,Zeng RH,Yin XL,Feng HD,Wei L.Similar ability of Fba A with M protein to elicit protective immunity against group A streptococcus challenge in mice.Cell Mol Immunol,2009,6(1):73-77.
[24]Sabharwal H,Michon F,Nelson D,Dong W,Fuchs K,Manjarrez RC,Sarkar A,Uitz C,Viteri-Jackson A,Suarez RS,Blake M,Zabriskie JB.Group A streptococcus(GAS)carbohydrate as an immunogen for protection against GAS infection.J Infect Dis,2006,193(1):129-135.
[25]Tsao N,Cheng MH,Yang HC,Wang YC,Liu YL,Kuo CF.Determining antibody-binding site of streptococcal pyrogenic exotoxin B to protect mice from group a streptococcus infection.PLo S One,2013,8(1):e55028.
[26]Kuo CF,Tsao N,Cheng MH,Yang HC,Wang YC,Chen YP,Lin KJ.Application of the C3-binding motif of streptococcal pyrogenic exotoxin B to protect mice from invasive group A streptococcal infection.PLo S One,2015,10(1):e0117268.
[27]Ulrich RG.Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.J Immune Based Ther Vaccines,2008,6:8.
[28]Bensi G,Mora M,Tuscano G,Biagini M,Chiarot E,Bombaci M,Capo S,Falugi F,Manetti AG,Donato P,Swennen E,Gallotta M,Garibaldi M,Pinto V,Chiappini N,Musser JM,Janulczyk R,Mariani M,Scarselli M,Telford JL,Grifantini R,Norais N,Margarit I,Grandi G.Multi high-throughput approach for highly selective identification of vaccine candidates:the Group A Streptococcus case.Mol Cell Proteomics,2012,11(6):M111.015693.
[29]Rivera-Hernandez T,Pandey M,Henningham A,Cole J,Choudhury B,Cork AJ,Gillen CM,Ghaffar KA,West NP,Silvestri G,Good MF,Moyle PM,Toth I,Nizet V,Batzloff MR,Walker MJ.Differing efficacies of lead group A Streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models.MBio,2016,7(3):pii:e00616-18.
[30]Andrey DO,Posfay-Barbe KM.Re-emergence of scarlet fever:old players return?Expert Rev Anti Infect Ther,2016,14(8):687-689.
[31]余步云,汤美安,钱孝贤,周汉建.80年代以来风湿热的回顾性分析(附341例报告).新医学,1994,(8):407-408.
[32]喻刚,杨京生,全家妩.A群链球菌四价重组蛋白的表达、纯化及其免疫原性.中国生物制品学杂志,2010,23(1):17-21.
[33]Ding Y,Ni Q,Liu J,Yu B.Immunogenicity of a divalent group A streptococcal vaccine.Rheumatol Int,2013,33(4):1013-1020.
[34]丁月霞,倪琼琼,刘金来.广州市儿童致咽炎β溶血性链球菌的流行情况及其emm基因分型.中山大学学报(医学科学版),2011,32(3):411-414.
[35]张代涛,杨鹏,吴双胜,赵佳琛,卢桂兰,郭婧,王全意,彭晓旻.2011-2014年北京地区儿童咽扁桃体炎感染病例A组链球菌emm分型研究.疾病监测,2015,30(11):917-921.
[36]曾锦婷,刘爱胜,房笃智,向华国,田郭军.深圳宝安区儿童感染致病性A群链球菌流行现状及emm基因分型研究.中国优生与遗传杂志,2016,24(7):123-125.
[2]Carapetis JR,Steer AC,Mulholland EK,Weber M.The global burden of group A streptococcal diseases.Lancet Infect Dis,2005,5(11):685-694.
[3]Bowen AC,MahéA,Hay RJ,Andrews RM,Steer AC,Tong SY,Carapetis JR.The global epidemiology of impetigo:a systematic review of the population prevalence of impetigo and pyoderma.PLo S One,2015,10(8):e0136789.
[4]Pfoh E,Wessels MR,Goldmann D,Lee GM.Burden and economic cost of group A streptococcal pharyngitis.Pediatrics,2008,121(2):229-234.
[5]Martin WJ,Steer AC,Smeesters PR,Keeble J,Inouye M,Carapetis J,Wicks IP.Post-infectious group A streptococcal autoimmune syndromes and the heart.Autoimmun Rev,2015,14(8):710-725.
[6]Mcmillan DJ,Drèze PA,Vu T,Bessen DE,Guglielmini J,Steer AC,Carapetis JR,Van Melderen L,Sriprakash KS,Smeesters PR.Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.Clin Microbiol Infect,2013,19(5):E222-E229.
[7]喻刚,董太明,全家妩.A群链球菌疫苗的研究进展.中国生物制品学杂志,2009,22(8):830-833.
[8]Dale JB,Penfound TA,Tamboura B,Sow SO,Nataro JP,Tapia M,Kotloff KL.Potential coverage of a multivalent M proteinbased group A streptococcal vaccine.Vaccine,2013,31(12):1576-1581.
[9]Sanderson-Smith M,De Oliveira DM,Guglielmini J,Mcmillan DJ,Vu T,Holien J K,Henningham A,Steer AC,Bessen DE,Dale JB,Curtis N,Beall BW,Walker MJ,Parker MW,Carapetis JR,Van Melderen L,Sriprakash KS,Smeesters PR;M Protein Study Group.A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.J Infect Dis,2014,210(8):1325-1338.
[10]Steer AC,Carapetis JR,Dale JB,Fraser JD,Good MF,Guilherme L,Moreland NJ,Mulholland EK,Schodel F,Smeesters PR.Status of research and development of vaccines for Streptococcus pyogenes.Vaccine,2016,34(26):2953-2958.
[11]Steer AC,Law I,Matatolu L,Beall BW,Carapetis JR.Global emm type distribution of group A streptococci:systematic review and implications for vaccine development.Lancet Infect Dis,2009,9(10):611-616.
[12]Dale JB,Niedermeyer SE,Agbaosi T,Hysmith ND,Penfound TA,Hohn CM,Pullen M,Bright MI,Murrell DS,Shenep LE,Courtney HS.Protective immunogenicity of group A streptococcal M-related proteins.Clin Vaccine Immunol,2015,22(3):344-350.
[13]Courtney HS,Niedermeyer SE,Penfound TA,Hohn CM,Greeley A,Dale JB.Trivalent M-related protein as a component of next generation group A streptococcal vaccines.Clin Exp Vaccine Res,2017,6(1):45-49.
[14]Batzloff M,Yan H,Davies M,Hartas J,Good M.Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection.Indian J Med Res,2004,119 Suppl:104-107.
[15]Pandey M,Wykes MN,Hartas J,Good MF,Batzloff MR.Longterm antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.J Immunol,2013,190(6):2692-2701.
[16]Batzloff MR,Fane A,Gorton D,Pandey M,Rivera-Hernandez T,Calcutt A,Yeung G,Hartas J,Johnson L,Rush CM,McCarthy J,Ketheesan N,Good MF.Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.Hum Vaccin Immunother,2016,12(12):3089-3096.
[17]Guilherme L,Postol E,Ferreira FM,De Marchi LM,Kalil J.Strept In Cor:a model of anti-Streptococcus pyogenes vaccine reviewed.Auto Immun Highlights,2013,4(3):81-85.
[18]Guilherme L,Ferreira FM,K9hler KF,Postol E,Kalil J.A vaccine against Streptococcus pyogenes:the potential to prevent rheumatic fever and rheumatic heart disease.Am J Cardiovasc Drugs,2013,13(1):1-4.
[19]Marshall HS,Richmond P,Nissen M,Lambert S,Booy R,Reynolds G,Sebastian S,Pride M,Jansen KU,Anderson AS,Scully IL.Group A streptococcal carriage and seroepidemiology in children up to 10 years of age in Australia.Pediatr Infect Dis J,2015,34(8):831-838.
[20]Cleary PP,Matsuka YV,Huynh T,Lam H,Olmsted SB.Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.Vaccine,2004,22(31-32):4332-4341.
[21]Steer AC,Batzloff MR,Mulholland K,Carapetis JR.Group A streptococcal vaccines:facts versus fantasy.Curr Opin Infect Dis,2009,22(6):544-552.
[22]Courtney HS,Pownall HJ.The structure and function of serum opacity factor:a unique streptococcal virulence determinant that targets high-density lipoproteins.J Biomed Biotechnol,2010,2010:956071.
[23]Ma CQ,Li CH,Wang XR,Zeng RH,Yin XL,Feng HD,Wei L.Similar ability of Fba A with M protein to elicit protective immunity against group A streptococcus challenge in mice.Cell Mol Immunol,2009,6(1):73-77.
[24]Sabharwal H,Michon F,Nelson D,Dong W,Fuchs K,Manjarrez RC,Sarkar A,Uitz C,Viteri-Jackson A,Suarez RS,Blake M,Zabriskie JB.Group A streptococcus(GAS)carbohydrate as an immunogen for protection against GAS infection.J Infect Dis,2006,193(1):129-135.
[25]Tsao N,Cheng MH,Yang HC,Wang YC,Liu YL,Kuo CF.Determining antibody-binding site of streptococcal pyrogenic exotoxin B to protect mice from group a streptococcus infection.PLo S One,2013,8(1):e55028.
[26]Kuo CF,Tsao N,Cheng MH,Yang HC,Wang YC,Chen YP,Lin KJ.Application of the C3-binding motif of streptococcal pyrogenic exotoxin B to protect mice from invasive group A streptococcal infection.PLo S One,2015,10(1):e0117268.
[27]Ulrich RG.Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.J Immune Based Ther Vaccines,2008,6:8.
[28]Bensi G,Mora M,Tuscano G,Biagini M,Chiarot E,Bombaci M,Capo S,Falugi F,Manetti AG,Donato P,Swennen E,Gallotta M,Garibaldi M,Pinto V,Chiappini N,Musser JM,Janulczyk R,Mariani M,Scarselli M,Telford JL,Grifantini R,Norais N,Margarit I,Grandi G.Multi high-throughput approach for highly selective identification of vaccine candidates:the Group A Streptococcus case.Mol Cell Proteomics,2012,11(6):M111.015693.
[29]Rivera-Hernandez T,Pandey M,Henningham A,Cole J,Choudhury B,Cork AJ,Gillen CM,Ghaffar KA,West NP,Silvestri G,Good MF,Moyle PM,Toth I,Nizet V,Batzloff MR,Walker MJ.Differing efficacies of lead group A Streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models.MBio,2016,7(3):pii:e00616-18.
[30]Andrey DO,Posfay-Barbe KM.Re-emergence of scarlet fever:old players return?Expert Rev Anti Infect Ther,2016,14(8):687-689.
[31]余步云,汤美安,钱孝贤,周汉建.80年代以来风湿热的回顾性分析(附341例报告).新医学,1994,(8):407-408.
[32]喻刚,杨京生,全家妩.A群链球菌四价重组蛋白的表达、纯化及其免疫原性.中国生物制品学杂志,2010,23(1):17-21.
[33]Ding Y,Ni Q,Liu J,Yu B.Immunogenicity of a divalent group A streptococcal vaccine.Rheumatol Int,2013,33(4):1013-1020.
[34]丁月霞,倪琼琼,刘金来.广州市儿童致咽炎β溶血性链球菌的流行情况及其emm基因分型.中山大学学报(医学科学版),2011,32(3):411-414.
[35]张代涛,杨鹏,吴双胜,赵佳琛,卢桂兰,郭婧,王全意,彭晓旻.2011-2014年北京地区儿童咽扁桃体炎感染病例A组链球菌emm分型研究.疾病监测,2015,30(11):917-921.
[36]曾锦婷,刘爱胜,房笃智,向华国,田郭军.深圳宝安区儿童感染致病性A群链球菌流行现状及emm基因分型研究.中国优生与遗传杂志,2016,24(7):123-125.